Affordable Access

deepdyve-link
Publisher Website

[HPV testing in the screening and follow-up of patients with cervical high-grade squamous intraepithelial lesions].

Authors
  • Gonthier, C1
  • Desportes, C2
  • Pretet, J-L3
  • Azaïs, H2
  • Uzan, C4
  • Mergui, J-L2
  • Canlorbe, G4
  • 1 Service de chirurgie et oncologie gynécologique et mammaire, hôpital Pitié-Salpêtrière, AP-HP, 47-83, boulevard de l'Hôpital, 75013 Paris, France. Electronic address: [email protected] , (France)
  • 2 Service de chirurgie et oncologie gynécologique et mammaire, hôpital Pitié-Salpêtrière, AP-HP, 47-83, boulevard de l'Hôpital, 75013 Paris, France. , (France)
  • 3 EA3181 carcinogenèse associée aux HPV, laboratoire de biologie cellulaire et moléculaire, Centre national de référence Papillomavirus, université Bourgogne Franche Comté, CHU de Besançon, boulevard A.-Fleming, 25030 Besançon cedex, France. , (France)
  • 4 Service de chirurgie et oncologie gynécologique et mammaire, hôpital Pitié-Salpêtrière, AP-HP, 47-83, boulevard de l'Hôpital, 75013 Paris, France; Biologie et thérapeutique du Cancer, Centre de recherche Saint-Antoine (CRSA), Sorbonne université, 184, rue du Faubourg Saint-Antoine, 75012 Paris, France. , (France)
Type
Published Article
Journal
Gynecologie, obstetrique, fertilite & senologie
Publication Date
Oct 01, 2019
Volume
47
Issue
10
Pages
747–752
Identifiers
DOI: 10.1016/j.gofs.2019.09.004
PMID: 31520818
Source
Medline
Keywords
Language
French
License
Unknown

Abstract

To evaluate the value of high-risk HPV (HR HPV) testing in screening and post-treatment follow-up of high-grade squamous intraepithelial cervical lesions (HSIL). A systematic review of the literature from 2000 to 2019 was conducted including the following keywords: "human papilloma virus", "HPV testing", "cervical squamous intraepithelial lesion", "cervical cancer". Numerous recent randomized studies and meta-analyzes have concordant results in favor of HR HPV superiority over cervical smear in the screening and post-treatment monitoring of HSIL. In screening, the sensitivity of the HR HPV tests is 63% to 98% whereas that of the cervical smear is only 38% to 65% for the detection of HSIL+ (HSIL and invasive cancers). A negative HR HPV test is associated with less than 5% risk of LIEHG+at 6 years. In addition, after removal of a LIEHG, HR HPV tests have a sensitivity>90% and specificity>80% to predict treatment failure. After surgicale exision, a negative HR HPV test is associated with a risk of failure<2% (negative predictive value of 98%), and 12-25% if it is positive. HR HPV tests are effective, allowing early detection of LIEHG+ identification of low-risk women in case of negative test, and a prediction of the risk of failure after treatment. Copyright © 2019 Elsevier Masson SAS. All rights reserved.

Report this publication

Statistics

Seen <100 times